Archives
Vancouver, British Columbia – September 21, 2017 – Sirona Biochem Corp. (TSX-V: SBM) (FRANKFURT: ZSB) is pleased to provide a corporate update.
Dear Shareholders,
I would like to thank you for your continued support while we work through the negotiations for our skin lightener. The following is an update on our progress to date.
Further in vivo and in vitro studies, including toxicology, are wrapping up now and results are expected by November. CMC (chemistry, manufacturing and control) studies on pharmaceutical grade batch preparations are complete and have met reference standards for use in clinical studies.
Wanbang expects to file the IND to the CFDA by the end of this year. This will trigger another milestone payment of $500,000 USD to Sirona.
Recently, the Indian subsidiary of a global pharmaceutical company has expressed interest in licensing SBM-TFC-039 for India and have begun due diligence.
Again, we thank you for your continued support and patience during this time.
Sincerely,
Dr. Howard Verrico, CEO
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.